



**Date:** 14-02-2026

To,  
BSE Limited  
Listing Department  
Phiroze Jeejeebhoy Towers,  
25th Floor, Dalal Street,  
Mumbai - 400 001

To,  
National Stock Exchange of India Limited  
Listing Department "Exchange Plaza,"  
C-1, Block G, Bandra - Kurla Complex  
Bandra (E),  
Mumbai - 400 051.

Scrip Code: 544666

Dear Sir/Madam

Sub: Outcome of Board Meeting held on 14<sup>th</sup> February, 2026

Pursuant to Regulations 30 and 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we hereby inform you that the Board of Directors of Gujarat Kidney and Super Speciality Limited ("the Company") at its meeting held today, i.e. Saturday, February 14, 2026, inter alia, considered and approved the following matters:

**1. Approval of Unaudited Financial Result**

The Board approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025, along with the Limited Review Report issued by the Statutory Auditors.

Copies of the following documents are enclosed below.

- Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025; and
- Limited Review Report of the Statutory Auditors thereon and any other business matters.

The meeting of the Board of Directors commenced at 5:00 (IST) and concluded at 6:00 (IST)

The above information is also available on the Company's website [www.gujaratsuperspecialityhospital.com](http://www.gujaratsuperspecialityhospital.com)

We request you to please take the above information on your records.

**For Gujarat Kidney and Super Speciality Limited**

**Niki Tiwari**  
Company secretary & Compliance Officer  
Membership No.45550  
Encl: as above



**Gujarat Kidney And Superspeciality Limited**

Formerly known as Gujarat Kidney And Superspeciality Private Limited / Previously known as Vihaan Medicare Private Limited

CIN : U85300GJ2019PLC111559

Reg. Office : Plot No.1, City Survey No 1537/A, Gokak Mill Compound, Jetalpur-Road, Alkapuri,  
Vadodara - 390020, Gujarat, India. E-mail : [gujaratkidneyhospital1@gmail.com](mailto:gujaratkidneyhospital1@gmail.com) / [www.gujaratsuperspecialityhospital.com](http://www.gujaratsuperspecialityhospital.com)

For Appointment Please Dial ☎ 0265 - 2984 800 / +91 96870 79991

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS**

To The Board of Directors of

Gujarat Kidney And Super Speciality Limited.

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Gujarat Kidney And Super Speciality Limited (the "Company") for the 3<sup>rd</sup> quarter and nine months ended 31<sup>st</sup> December 2025 (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and analytical procedures and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an Audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (Ind AS) and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed or that it contains any material misstatement.

**Date: 14-02-2026**

**Place: Vadodara**



**FOR Y. M. SHAH & Co.**  
Chartered Accountants  
F. R. No.: 114124W



Harsh Shah  
Partner

M. No. 188123  
UDIN: 26188123TZNDAT3577

# GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

CIN: U85300GJ2019PLC111559

Address. Plot No.1 city survey no 1573/A, Jetalpur Road, Gokak Mill Compound, Alkapuri, Vadodara - 390020

## Standalone Financial Result for the period ended on 31 December 2025

Rs. in Lacs

Sr No	Particulars	Quarter Ended			Nine month ended		Year Ended
		31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
I	<b>Income</b>						
	Revenue From Operations	976.45	964.26	850.64	3,085.70	2,715.08	3,516.70
	Other Income	2.73	1.51	2.19	4.39	7.30	11.41
	<b>Total Income (I)</b>	979.18	965.77	852.83	3,090.09	2,722.38	3,528.11
II	<b>Expenses</b>						
	Cost of materials consumed	113.41	113.50	94.17	351.52	265.29	373.55
	Employee benefits expense	143.45	133.54	171.55	413.94	511.57	652.78
	Finance costs	29.22	23.33	10.68	65.24	41.20	53.11
	Depreciation and amortization expense	71.73	75.49	65.88	227.00	217.27	292.65
	Other expenses	305.08	307.47	204.35	863.41	624.76	946.35
	<b>Total expenses (II)</b>	662.89	653.33	546.63	1,921.11	1,660.09	2,318.44
III	<b>Profit/(loss) before tax (I-II)</b>	316.29	312.44	306.20	1,168.98	1,062.29	1,209.67
IV	<b>Tax expense</b>						
	Current tax	85.70	86.20	87.53	327.27	298.93	338.04
	Deferred tax	(2.67)	(3.88)	(16.66)	(11.65)	(35.19)	(53.40)
	Prior period tax	-	-	14.13	-	14.13	14.13
	<b>Total Tax expense (IV)</b>	83.03	82.32	85.00	315.62	277.87	298.77
V	<b>Profit/(loss) after tax for the period (III-IV)</b>	233.26	230.12	221.20	853.36	784.42	910.90
VI	<b>Other Comprehensive Income</b>						
	Items that will not be reclassified to profit or loss	2.66	2.76	5.04	6.87	8.63	13.67



# GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

CIN: U85300GJ2019PLC111559


Address. Plot No.1 city survey no 1573/A, Jetalpur Road, Gokak Mill Compound, Alkapuri, Vadodara - 390020

## Standalone Financial Result for the period ended on 31 December 2025

Rs. in Lacs

Sr No	Particulars	Quarter Ended			Nine month ended		Year Ended
		31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
	Income tax relating to items that will not be reclassified to profit or loss	(0.67)	(0.70)	(1.27)	(1.73)	(2.17)	(3.44)
	Total Other Comprehensive Income (VI)	1.99	2.06	3.77	5.14	6.46	10.23
VII	Total Comprehensive Income for the period (V+VI)	235.25	232.18	224.97	858.50	790.88	921.13
VIII	Earnings per equity share						
	Basic	0.41	0.40	0.46	1.50	1.64	1.79
	Diluted	0.41	0.40	0.46	1.50	1.64	1.79

For and on behalf of Board of Directors,  
GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED



Dr Pragnesh Y Bharpoda  
Managing Director  
DIN: 01033141  
Place: Vadodara  
Date: 14/02/2026




## REKVINA LABORATORIES LIMITED

Notes to the Standalone Financial Result for the period ended on 31 March 2025

- 1 The Above Standalone Quarterly Unaudited Financial Results of M/s. Gujarat Kidney & Superspeciality Limited for the quarter and half yearly have been reviewed and recommended by the Audit Committee and the same has been approved by the Board of Directors of the Company at its meeting held on 14.02.2026. This Results have been subjected to limited Review by the statutory Auditor of the company M/s Y M Shah & Co. who have issued unmodified limited review report.
- 2 These stand alone financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind A5) 34 - Interim Financial Reporting, as prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder, and in compliance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other accounting principles generally accepted in India
- 3 As the Company's business activity falls within a single primary business segment, namely dealing in Trading of Pharma Goods, the disclosure requirements as per Ind-AS 108 "operating segments" are not applicable.
- 4 The Earing Per Shares has been computed in accordance with Indian Accounting Standard on Earing Per Shares (IND AS 33).
- 5 This statement is prepared as per Indian Accounting Standards (IND AS) notified under section 133 under Companies Act, 2013 read with Companies Act 2015 (Indian Accounting Standard Rules) as ammended and as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- 6 Previous period's / year figures have been regrouped / rearranged wherever consider necessary to confirm to the current period's / year classification.

For and on behalf of Board of Directors,  
GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED



Dr Pragnesh Y Bharpoda  
Managing Director  
DIN: 01033141

Place: Vadodara  
Date: 14/02/2026



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS**

To The Board of Directors of

**Gujarat Kidney And Super Speciality Limited.**

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **Gujarat Kidney And Super Speciality Limited** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income (net) of its associates and joint ventures for the 3<sup>rd</sup> quarter and nine months ended 31<sup>st</sup> December 2025 (the "Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Parent's personnel responsible for financial and accounting matters, and analytical procedures and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an Audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Company	Relationship
Gujarat Surgical Hospital	Entity under Control
Surya Hospital and ICU	Entity under Control
Raj Palmland Hospital Private Limited	Subsidiary
Harmcny Medicare Private Limited	Subsidiary



5. Based on our review conducted and procedures performed as stated above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (Ind AS) and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed or that it contains any material misstatement.
6. We did not review the interim financial results/financial information of 2 subsidiaries and 2 Entities under control included in the consolidated unaudited financial results. These interim financial results/financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amount and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.


Our conclusion on the Statement is not modified in respect of these matters.

**Date: 14-02-2026**

**Place: Vadodara**



**FOR Y. M. SHAH & Co.**  
Chartered Accountants  
F. R. No.: 114124W



Harsh Shah  
Partner

M. No. 188123

UDIN: 26188123RZVYEB6239

# GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

CIN: U85300GJ2019PLC111559

Address. Plot No.1 city survey no 1573/A, Jetalpur Road, Gokak Mill Compound, Alkapuri, Vadodara - 390020

Consolidated Financial Result for the period ended on 31 December 2025

Rs. in Lacs

Sr No	Particulars	Quarter Ended			Nine month ended		Year Ended
		31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
I	<b>Income</b>						
	Revenue From Operations	2,324.59	1,292.88	1,178.93	5,143.49	3,045.98	4,024.21
	Other Income	6.32	8.79	5.29	15.94	10.40	15.49
	<b>Total Income (I)</b>	<b>2,330.91</b>	<b>1,301.67</b>	<b>1,184.22</b>	<b>5,159.43</b>	<b>3,056.38</b>	<b>4,039.70</b>
II	<b>Expenses</b>						
	Cost of materials consumed	305.33	130.10	103.27	574.54	239.82	396.34
	Employee benefits expense	398.45	222.63	295.13	829.31	636.14	835.29
	Finance costs	59.85	28.10	16.65	106.02	48.22	64.63
	Depreciation and amortization expense	132.99	89.95	87.82	319.35	239.21	329.04
	Other expenses	931.37	427.83	321.22	1,675.32	776.86	1,137.88
	<b>Total expenses (II)</b>	<b>1,827.99</b>	<b>898.61</b>	<b>824.09</b>	<b>3,504.54</b>	<b>1,940.25</b>	<b>2,763.18</b>
III	<b>Profit/(loss) before tax (I-II)</b>	<b>502.92</b>	<b>403.06</b>	<b>360.13</b>	<b>1,654.89</b>	<b>1,116.13</b>	<b>1,276.52</b>
IV	<b>Tax expense</b>						
	Current tax	139.72	116.01	111.88	469.83	323.28	367.21
	Deferred tax	(7.42)	(0.59)	(19.43)	(13.52)	(37.96)	(54.76)
	Prior period tax	-	-	14.13	-	14.13	14.13
	<b>Total Tax expense (IV)</b>	<b>132.30</b>	<b>115.42</b>	<b>106.58</b>	<b>456.31</b>	<b>299.45</b>	<b>326.58</b>
V	<b>Profit/(loss) after tax for the period (III-IV)</b>	<b>370.62</b>	<b>287.64</b>	<b>253.55</b>	<b>1,198.58</b>	<b>816.68</b>	<b>949.94</b>
VI	<b>Other Comprehensive Income</b>						
	Items that will not be reclassified to profit or loss	3.61	4.78	5.04	9.13	31.28	33.70
	Income tax relating to items that will not be reclassified to profit or loss	(0.92)	(1.32)	(1.27)	(2.43)	(2.17)	(2.78)
	<b>Total Other Comprehensive Income (VI)</b>	<b>2.69</b>	<b>3.46</b>	<b>3.77</b>	<b>6.70</b>	<b>29.11</b>	<b>30.92</b>
VII	<b>Total Comprehensive Income for the period (V+VI)</b>	<b>373.31</b>	<b>291.10</b>	<b>257.32</b>	<b>1,205.28</b>	<b>845.79</b>	<b>980.86</b>

*P. J. Bhargava*  


# GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

CIN: U85300GJ2019PLC111559

Address: Plot No.1 city survey no 1573/A, Jetalpur Road, Gokak Mill Compound, Alkapuri, Vadodara - 390020

Consolidated Financial Result for the period ended on 31 December 2025

Rs. in Lacs

Sr No	Particulars	Quarter Ended			Nine month ended		Year Ended
		31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
VIII	<b>Profit/(loss) after tax for the period (III-IV) attributable to:</b>						
	-Owners of the company	294.15	266.87	250.42	1,045.51	813.56	941.31
	-Non-Controlling Interests	76.47	20.77	3.13	153.08	3.13	8.63
		370.62	287.64	253.55	1,198.59	816.68	949.94
IX	<b>Total Other Comprehensive Income (VI) attributable to:</b>						
	-Owners of the company	2.68	3.32	3.77	6.84	29.11	31.88
	-Non-Controlling Interests	0.01	0.14	-	(0.14)	-	(0.96)
		2.69	3.46	3.77	6.70	29.11	30.92
X	<b>Total Comprehensive Income for the period (V+VI) attributable to:</b>						
	-Owners of the company	296.84	270.20	254.19	1,052.35	842.67	973.19
	-Non-Controlling Interests	76.48	20.90	3.13	152.94	3.13	7.67
		373.31	291.10	257.32	1,205.29	845.80	980.86
XI	<b>Earnings per equity share</b>						
	Basic	0.52	0.47	0.52	1.84	1.70	1.85
	Diluted	0.52	0.47	0.52	1.84	1.70	1.85

For and on behalf of Board of Directors,

GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

*Dr Pragnesh Y Bharpoda*  
Dr Pragnesh Y Bharpoda

Managing Director

DIN: 01033141

Place: Vadodara

Date: 14/02/2026




## REKVINA LABORATORIES LIMITED

Notes to the Standalone Financial Result for the period ended on 31 March 2025

- 1 The Above Consolidated Quarterly Unaudited Financial Results of M/s. Gujarat Kidney & Superspeciality Limited for the quarter and half yearly have been reviewed and recommended by the Audit Committee and the same has been approved by the Board of Directors of the Company at its meeting held on 14.02.2026. This Results have been subjected to limited Review by the statutory Auditor of the company M/s Y M Shah & Co. who have issued unmodified limited review report.
- 2 These Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind A5) 34 - Interim Financial Reporting, as prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder, and in compliance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other accounting principles generally accepted in India
- 3 As the Company's business activity falls within a single primary business segment, namely dealing in Trading of Pharma Goods, the disclosure requirements as per Ind-AS 108 "operating segments" are not applicable.
- 4 The Earing Per Shares has been computed in accordance with Indian Accounting Standard on Earing Per Shares (IND AS 33).
- 5 This statement is prepared as per Indian Accounting Standards (IND AS) notified under section 133 under Companies Act, 2013 read with Companies Act 2015 (Indian Accounting Standard Rules) as ammended and as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- 6 Previous period's / year figures have been regrouped / rearranged wherever consider necessary to confirm to the current period's / year classification.

For and on behalf of Board of Directors,  
GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED



Dr Pragnesh Y Bharpoda  
Managing Director  
DIN: 01033141



Place: Vadodara  
Date: 14/02/2026